Remove Consulting Remove Individual Remove Manufacturing Remove Medical
article thumbnail

The Rising Tide of Medical Waste: One Model for Improvement

My Green Doctor

Author: Ishani Majmudar Medical waste is rising tremendously each year, and its implications are not slight. Medical waste is a broad term used to describe any waste products generated at healthcare facilities and includes everything ranging from the disposal of small needles to the energy consumption of radiologic scans. 3 “Each U.S.

Medical 52
article thumbnail

How to Get Ozempic & GLP-1’s Covered by Insurance (or Save Big with Plum Health Direct Primary Care): The Ultimate Guide You Can’t Afford to Miss!

Plum Health

Update: Click here to book a free 30 minute in-person consultation with Dr. Sharon or Dr. Mike to discuss affordable GLP-1 medication! These are groundbreaking medications that not only help regulate blood sugar but also support weight loss. Unfortunately, their cost often makes them inaccessible to those who need them most.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Green Practice News: May 2025

My Green Doctor

In This Issue : Why Renewable Energy Belongs in Every Clinic Medical Waste: One Model for Improvement OnTrack with your Sustainability Goals? Our Consulting Services offer customized strategies for group practices, health systems, and medical societies ready to accelerate their impact and lead the way in climate-smart care.

article thumbnail

Warning Letters: An Untapped Source for Understanding When Device Changes Require a New 510(k)

FDA Law

Manufacturers must evaluate device changes in the first instance to determine whether a new 510(k) is needed or, instead, whether documentation of the change and rationale for not seeking 510(k) clearance is sufficient. Such assessments are highly individualized and difficult to map onto the few examples provided by FDA in its guidance.

article thumbnail

Senators to DEA: Consider Treaty Obligations In Marijuana Rescheduling

FDA Law

Schedule IV substances are highly addictive and rarely used in medical practice while schedule I substances are also highly addictive, liable to abuse or convertible to drugs similarly addictive and liable to abuse. The Single Convention imposes more stringent controls on schedule IV substances than on schedule I substances. 811(d) and U.S.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

We talk with Nick and Meg about: Why hearing loss is important not just in geriatrics but also for those caring for seriously ill individuals. Communication techniques we can use when talking to individuals with hearing loss. But individuals who have hearing loss, there’s several problems. How to screen for hearing loss.

IT 102
article thumbnail

The FDA PDUFA VII Goals Letter (FY 2023-2027): A Review of Our Top 10 Commitments

FDA Law

STAR aims to facilitate earlier access to novel uses of existing therapies for patients with a serious condition with unmet medical needs. 30, 2023; Public workshop on advancing innovative manufacturing technology, by end of FY 2023; Publish advancing innovative manufacturing technology strategy document, by Sept.